To investigate whether low expression of MTAP is associated with specific baseline clinical features in patients with AML, we compared the frequency of MTAP low expression according to diagnosis age, sex, BM blast percentage, white blood cell count, peripheral blasts percentage, cytogenetic risk and molecular risk (Tables S1 and S2). The gene discussed is MTAP; the disease is acute myeloid leukemia.